Gut microbes
Cure8 research brief
Why This Matters
Treatment resistance is a major hurdle in IBD care; this review maps how microbiota, immune imbalance, and epigenetics may work together to cause drug-resistant disease and suggests potential precision strategies that could eventually improve outcomes.
Who Should Pay Attention
Researchers studying IBD mechanisms or therapies, clinicians managing patients with primary or secondary loss of response to biologics or JAK inhibitors, and patients curious about emerging microbiome- or epigenetics-based approaches.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a review article (abstract-level) that analyzes mechanisms of drug resistance in IBD centered on interactions among the gut microbiota, immune responses, and epigenetic changes.
It proposes a "triple-loop hierarchical regulation model," defines four resistance subtypes, and discusses targeted strategies such as microbiota modulation (including fecal microbiota transplantation), epigenetic-targeting agents (e.g., histone deacetylase inhibitors), and multi-omics biomarkers.
It highlights cutting-edge methods like single-cell multi-omics and organoid–microbiota co-cultures.
Keep In Mind
This record is a journal review (abstract provided) synthesizing preclinical and clinical literature and proposing a conceptual model. Proposed interventions (fecal microbiota transplantation, HDAC inhibitors, multi-omics biomarkers) are discussed as research or translation opportunities rather than established clinical standards.
The abstract-level source does not report new trial results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationGut microbes
AuthorsQing Li, Mingrong Cheng, Xiaoyue Wang +2 more
InstitutionDepartment of General Practice, Minhang District Pujin Community Health Service Center, Shanghai, China.
Study typeJournal article, review
Indexed viaPubMed
Source typeResearch paper
PublishedSep 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FUT2-mediated α1,2-fucosylation in inflammatory bowel disease: mechanisms and translational potential.
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
Ferroptosis in Intestinal Diseases: Molecular Mechanisms, Therapeutic Potential, and Future Perspectives.
Researchers are exploring ferroptosis as a double-edged mechanism: preventing it may protect healthy gut lining in IBD, while inducing it might help treat colorectal cancer. Advances could lead to new biomarkers or...
Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...